Webcast

Manifestations of Gaucher Disease: Rare or Under-recognized?

Launch Date
02/23/2023
Credit Amount
1.00 Hours
Credit Expires
02/23/2024

Faculty

Tamanna Roshan Lal, MB, ChB, FAAP, FACMG
Medical Geneticist
Director of Clinical Trials
Rare Disease Institute, Children's National Hospital, Washington, DC
Tamanna Roshan Lal, MB, ChB, FAAP, FACMG

Dr. Roshan Lal is a Pediatric Clinical and Metabolic Geneticist working at the Rare Disease Institute, Children’s National Hospital in Washington DC. Her clinical and research interests are geared towards improving the quality of life for children with rare genetic diseases, specifically lysosomal storage diseases and neuro-genetic disorders. Her special interest includes being involved in clinical trials using orphan drugs as well as gene therapy. She is currently the Director of Clinical Trials and Director of International Patient Consultations and Care Referrals for the Rare Disease Institute at the Children’s Hospital.

Coy Heldermon, MD, PhD
Associate Professor, UFHealth
Director of the Pediatric and Adult Multi-Disciplinary Lysosomal Storage Disease Clinics, Gainesville, FL
Coy Heldermon, MD, PhD

Dr. Coy Heldermon is an associate professor of medicine and board-certified medical oncologist at the University of Florida with expertise in the treatment of breast cancer. He is a member of the American Society of Hematology and the American Society of Clinical Oncology. His research expertise is in the use of gene replacement and stem cell therapies for the treatment of inherited disorders such as lysosomal storage diseases.

Dimitri Krainc, MD, PhD
Chair, Department of Neurology
Director, Simpson Querrey Center for Neurogenetics
Aaron Montgomery Ward Professor, Northwestern University Feinberg School of Medicine, Chicago, IL
Dimitri Krainc, MD, PhD

Dimitri Krainc, MD, PhD, currently serves as the Ward Professor and Chairman of the Department of Neurology and Director of the Simpson Querrey Center for Neurogenetics at Northwestern University, Feinberg School of Medicine in Chicago. Previously, he spent over two decades at Massachusetts General Hospital and Harvard Medical School where he completed his research and clinical training and served on the neurology faculty. His group discovered how to improve degradation of aggregation-prone proteins such as mutant huntingtin and a-synuclein by the lysosomal pathway. They identified a positive feedback loop between alpha-synuclein and lysosomal glucocerebrosidase in synucleinopathies. Using patient-specific neurons, his lab discovered a link between mitochondrial and lysosomal dysfunction in neurodegeneration of human but not mouse midbrain neurons. Based on these findings, Dr. Krainc’s group initiated the development of activators of lysosomal glucocerebrosidase as targeted therapeutics for Parkinson’s disease. Their recent discovery of direct contacts between mitochondria and lysosomes and organelle dynamics has implications for various neurological and other disorders. He received numerous awards for his work and is an elected member of the Association of American Physicians and the National Academy of Medicine.

Neal J. Weinreb, MD, FACP
Voluntary Associate Professor
Department of Human Genetics
University of Miami Miller School of Medicine, Miami, FL
Neal J. Weinreb, MD, FACP

Neal J. Weinreb, MD, FACP is a graduate of the Jewish Theological Seminary (Bachelor of Hebrew Literature), and SUNY Downstate Health Sciences University (MD, summa cum laude). After a residency in Internal Medicine at Albert Einstein College of Medicine and a fellowship and faculty position at Mt. Sinai School of Medicine, NY, he practiced Hematology and Medical Oncology in South Florida. Dr. Weinreb, the director of the University Research Foundation for Lysosomal Storage Diseases in Boca Raton, FL, retired from clinical practice in May 2018. He now devotes his entire professional attention to clinical research about Gaucher Disease and Fabry Disease. Dr Weinreb is a Voluntary Associate Professor of Human Genetics and Medicine at the University of Miami Miller School of Medicine. Dr. Weinreb is an investigator for the Gaucher and Fabry Registries and a member of the Medical Advisory Board for the National Gaucher Foundation and of the International Working Group for Gaucher Disease.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Additional Formats

Statement of Need

Gaucher disease (GD) is a genetic disorder that causes fatty substances to accumulate to harmful levels in organs and tissues, often resulting in hepatosplenomegaly, anemia, thrombocytopenia, bone pain and fractures, and conditions like arthritis. GD is rare, and even specialists struggle to recognize and diagnose the condition. Delays to initiation of therapy are common and can result in irreversible complications.

During this 60-minute symposium live, expert panelists will discuss GD, including its less commonly reported manifestations, diagnostic pathways, and patient-centric multidisciplinary management of the disorder.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Identify under-recognized clinical manifestations of GD.
  • Evaluate the efficacy of current diagnostic methods in recognizing rare manifestations in GD.
  • Implement patient-centric management strategies within a multidisciplinary team to optimize long-term outcomes of patients with GD.

Financial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

Physicians, PAs, nurse practitioners, PCPs, nurses, pharmacists, genetic counselors, and pediatricians, specializing in hematology, neurology, hepatology, gastroenterology, pulmonologists, radiology, and orthopedic surgery.

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME)

CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists/Pharmacy Tech (ACPE)

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.
Activity UAN: JA0007185-0000-23-006-L01-P

Nurses (ANCC)

This activity is designated for 1.0 contact hour.

Note for California Nurses

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters LLC’s provider number is CEP15510.

PAs (AAPA)

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until the expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit ™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Roshan Lal reports the following financial relationships: Advisory Board: Takeda Pharmaceuticals U.S.A., Inc. (Gaucher Advisory Board) Consultant: FDNA INC. Speakers Bureau: BioMarin (PKU).

Dr. Heldermon reports the following financial relationships: Advisory Board: Chiesi USA, Inc.; Orphazyme; REGENXBIO Inc.; and Sanofi. Consultant: Atheneum; Cardinal Health; Curio Science; Guidepoint Global; IntrinsiQ Specialty Solutions; Reckner Healthcare; Sage Research; Sanofi; Targeted Oncology; and Third Bridge Consulting; stock shareholder (ownership Interest): Lacerta Therapeutics.

Dr. Krainc reports no financial relationships to disclose.

Dr. Weinreb reports the following financial relationships: Advisory Board: AVROBIO, Inc. (Disease Monitoring Safety Board); Pfizer Inc. (Medical Advisory Board for the Taliglucerase alfa Gaucher Registry); Sanofi (Scientific Advisory Board for the International Collaborative Gaucher Group (ICGG) Gaucher Registry); and Takeda Pharmaceuticals U.S.A., Inc. (Medical Advisory Board for Gaucher Disease). Consultant: Pfizer Inc. and Sanofi. Speakers Bureau: Sanofi.

The following peer reviewer and CME Outfitters staff have no financial relationships:

  • Jeffrey Helfand, DO (peer reviewer)
  • Thomas Mitchell (planning committee)
  • Kellie Busby, PharmD (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Additional Formats

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-23-006-L01-P

 

Questions about this activity?

Call us at (877) CME-PROS or (877) 263-7767.

MMS-129-022323-20

Related Activities

Hematology
05/11/2022

Novel Approaches to Treating CMV Infection in People Receiving Solid Organ or Hematopoietic Stem Cell Transplantations

0.75 Hours
Begin Learn More
Hematology
06/22/2021

Cutting Through Comorbidities: Clearing the Way to Appropriate Anticoagulant Therapy in Patients at Risk for Deep Vein Thrombosis and Pulmonary Embolism

0.00 Expired
Begin Learn More
Diversity & Inclusion
10/11/2022

Racial and Ethnic Disparities and Health Inequities in Multiple Myeloma

0.5
Begin Learn More
Manifestations of Gaucher Disease: Rare or Under-recognized?
Event Date: 02/23/2023
Begin